7 result(s) for
PI Name | Protocol # | Title |
---|---|---|
Stephen Spurgeon | IRB00011766 | A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined with Induction in Acute Leukemias who Exhibit in vitro Kinase Inhibitor sensitivity |
Raymond Bergan | STUDY00015588 | Serial Measurements of Molecular and Architectural Responses to Therapy |
Uma Borate | STUDY00016363 | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis |
Uma Borate | STUDY00018059 | A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Secondary Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. |
Rachel Cook | STUDY00018380 | An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant |
Uma Borate | STUDY00019144 | A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera |
Michael Heinrich | STUDY00019801 | [NCI CIRB] - S1712 - A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease |